North America is the largest region in the global primary aldosteronism market, accounting for 38.2% of 2025 revenue, or USD 0.68 billion. Contrive Datum Insights expects that figure to reach USD 1.27 billion by 2034, according to its report "Primary Aldosteronism Market Size, Share & Industry Analysis."
Regional Picture
The global market was valued at USD 1.78 billion in 2025 and is projected to reach USD 1.93 billion in 2026 and USD 3.62 billion by 2034, a compound annual growth rate of 8.19% over the forecast period.
North America's lead is wide. Asia Pacific is second, with 24.16% of global revenue in 2025 (USD 0.43 billion), and its share is projected to climb to 27.9% by 2034 as revenue grows to USD 1.01 billion. Middle East and Africa remains the smallest region throughout, at 4.49% of 2025 revenue and 4.97% by 2034. At country level, the United States is the largest single market at USD 0.56 billion in 2025, or 31.46% of global revenue.
The market covers the diagnostic and therapeutic pathway that begins when excess aldosterone from the adrenal glands is suspected as the cause of a patient's hypertension. That includes biochemical screening, adrenal vein sampling, imaging to tell a unilateral adenoma from bilateral hyperplasia, and the drugs and operations used to treat each. Buyers include hospital endocrinology and interventional radiology departments, specialty endocrine clinics, imaging centers and surgical centers.
Segments and Risk
By type, Bilateral Adrenal Hyperplasia (BAH) is both the largest and the fastest-growing line. It held 57.87% of 2025 revenue, worth USD 1.03 billion, and is projected to grow at 8.93%, lifting its share to 61.88% by 2034. Aldosterone-Producing Adenoma (APA) holds 42.13% of 2025 revenue and grows at 7.06%, below the market's overall pace.
The other segment axes show a similar concentration in established care settings. Pharmaceuticals led by product type with 56.18% of revenue (USD 1 billion), and Medical Management (Pharmacotherapy) led by treatment approach with 67.98% (USD 1.21 billion). Among end users, Hospitals took 43.82% of 2025 revenue, worth USD 0.78 billion, while Specialty Clinics & Endocrinology Centers is the fastest-growing at 9.31%.
The main risk to North America's position, and to the forecast as a whole, is diagnosis. The study rates rising screening among resistant-hypertension patients as the largest single contributor to growth. In its bear case, screening uptake stalls near current levels and adrenal vein sampling capacity stays constrained, leaving more cases undiagnosed and untreated, and 2034 revenue is held to USD 3.14 billion. A bull case, in which aldosterone-renin ratio screening spreads into routine primary care hypertension workups, would lift 2034 revenue to USD 4.03 billion against the USD 3.62 billion base case. As the region with the largest share of revenue today, North America has the most at stake in either direction.
The report segments the market across four axes (type, product type, treatment approach and end user), with revenue and growth rates for every line from 2020 to 2034. It covers all five regions with country-level breakdowns, the competitive landscape and the research methodology behind each estimate. It is delivered as a PDF, and a free sample is available on request.